CancerDrs

Cervical Cancer clinical trials in Louisiana

15 actively recruiting cervical cancer trials at 7 sites across Louisiana.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Industry

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.

Sponsor: Merus B.V.
NCT ID: NCT06496178
Sites in Louisiana:
  • Site 40 — Baton Rouge, Louisiana
  • Site 100 — New Orleans, Louisiana
Phase 3 Recruiting Industry

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

This study will have two phases: a sacituzumab tirumotecan safety run-in and a Phase 3 portion. The safety run-in phase will be used to evaluate the efficacy and safety of sacituzumab tirumotecan at the dose for evaluation in the Phase 3 p…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06459180
Sites in Louisiana:
  • University Medical Center New Orleans ( Site 4132) — New Orleans, Louisiana
  • Willis Knighton Medical Center ( Site 4101) — Shreveport, Louisiana
Phase 3 Recruiting Industry

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progres…

Sponsor: AstraZeneca
NCT ID: NCT06079671
Sites in Louisiana:
  • Research Site — New Orleans, Louisiana
  • Research Site — New Orleans, Louisiana
  • Research Site — Shreveport, Louisiana
Phase 3 Recruiting Industry

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to …

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07216703
Sites in Louisiana:
  • TRIALS 365 ( Site 6008) — Shreveport, Louisiana
Phase 2 Recruiting NIH

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy and cispl…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07195734
Sites in Louisiana:
  • LSU Health Baton Rouge-North Clinic — Baton Rouge, Louisiana
  • Our Lady of the Lake Physician Group — Baton Rouge, Louisiana
Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…

Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Louisiana:
  • Local Institution - 2116 — New Orleans, Louisiana
Phase 2 Recruiting Industry

RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer

The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the incidence of severe oral mucositis in patients with head and neck cancers. All patients in this study will receiv…

Sponsor: EpicentRx, Inc.
NCT ID: NCT05966194
Sites in Louisiana:
  • Willis Knighton Cancer Center — Shreveport, Louisiana
Phase 2 Recruiting NIH

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

This phase II trial compares the effectiveness of cemiplimab with CDX-1140 to cemiplimab without CDX-1140 prior to surgery in treating patients with stage III-IV head and neck cancer. Immunotherapy with monoclonal antibodies, such as cemip…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06980038
Sites in Louisiana:
  • Ochsner Medical Center Jefferson — New Orleans, Louisiana
Phase 1 Recruiting Industry

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.

Sponsor: Coherus Oncology, Inc.
NCT ID: NCT06657144
Sites in Louisiana:
  • Ochsner Health — New Orleans, Louisiana
EARLY Phase 1 Recruiting Industry

A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors

This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0111 when administered intratumorally in microdose quantiti…

Sponsor: Pure Biologics S.A.
NCT ID: NCT06700070
Sites in Louisiana:
  • LSU Health Sciences Center — Shreveport, Louisiana
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Louisiana:
  • LSU Health Baton Rouge-North Clinic — Baton Rouge, Louisiana
  • Our Lady of the Lake Physician Group — Baton Rouge, Louisiana
  • Our Lady of The Lake — Baton Rouge, Louisiana
  • Louisiana Hematology Oncology Associates LLC — Baton Rouge, Louisiana
  • Louisiana Hematology Oncology Associates — Baton Rouge, Louisiana
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Louisiana:
  • Massive Bio SYNERGY-AI site — New Orleans, Louisiana
Recruiting Academic/Other

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus…

Sponsor: Mayo Clinic
NCT ID: NCT05051722
Sites in Louisiana:
  • Ochsner Clinic Foundation — New Orleans, Louisiana
NA Recruiting NIH

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)

This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention. HPV is a comm…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07281430
Sites in Louisiana:
  • Louisiana State University — Lafayette, Louisiana
  • Louisiana State University Health Science Center — New Orleans, Louisiana
Phase 4 Recruiting Academic/Other

Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV

The primary objective of this study is to determine the magnitude and breadth of the serum antibody response to the nonavalent HPV vaccine (Gardasil-9) in adults with well-controlled HIV infection. The secondary objectives of the study are…

Sponsor: Louisiana State University Health Sciences Center in New Orleans
NCT ID: NCT05266898
Sites in Louisiana:
  • University Medical Center New Orleans — New Orleans, Louisiana

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25